Inhibition of neuropeptide Y Y1 receptor induces osteoblast differentiation in MC3T3‑E1 cells

Yahara,Motoki; Tei,Kanchu; Tamura,Masato

doi:10.3892/mmr.2017.6866

Inhibition of neuropeptide Y Y1 receptor induces osteoblast differentiation in MC3T3‑E1 cells

Authors:
- Motoki Yahara
- Kanchu Tei
- Masato Tamura
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060‑8586, Japan, Department of Oral and Maxillofacial Surgery, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060‑8586, Japan
Published online on: June 27, 2017 https://doi.org/10.3892/mmr.2017.6866
Pages: 2779-2784

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuropeptide Y (NPY) is a major neural signaling molecule. NPY is produced by peripheral tissues, such as osteoblasts, and binds to the corresponding Y1 receptor that belongs to the G‑protein‑coupled receptor family. Osteoblast‑specific Y1 receptor knockout mice exhibit high bone mass, indicating a role of the NPY‑Y1 receptor axis in the regulation of bone homeostasis. In the bone microenvironment, peripheral nerve fibers and osteoblasts produce NPY. However, the effects of the Y1 receptor on osteoblasts remain unexplored. In the present study, an RNA interference approach was employed to target the Y1 receptor, in order to determine whether it may function to regulate the growth, differentiation and viability of osteoblasts. Knockdown of the Y1 receptor by small interfering RNA (siRNA) lead to induction of alkaline phosphatase (ALP) activity and mineralization in mouse MC3T3‑E1 osteoblast cells. In addition, the mRNA expression levels of ALP, osteocalcin, collagen (I) α1, and bone sialoprotein were significantly increased following transfection of a Y1 receptor siRNA. Furthermore, the mRNA expression levels of Runx2 and osterix were significantly increased; however, no significant alterations in cell proliferation and caspase‑3/7 activity were observed in Y1 receptor siRNA‑transfected cells when compared with non‑targeting controls. The results demonstrate that Y1 receptor inhibition may increase osteoblastic differentiation, which indicates a role of the Y1 receptor in the regulation of osteoblastic differentiation.

View Figures

View References

1	Baraban SC: Neuropeptide Y and limbic seizures. Rev Neurosci. 9:117–128. 1998. View Article : Google Scholar : PubMed/NCBI
2	Cerdá-Reverter JM and Larhammar D: Neuropeptide Y family of peptides: Structure, anatomical expression, function, and molecular evolution. Biochem Cell Biol. 78:371–392. 2000. View Article : Google Scholar : PubMed/NCBI
3	Silva AP, Cavadas C and Grouzmann E: Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta. 326:3–25. 2002. View Article : Google Scholar : PubMed/NCBI
4	Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, et al: Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 13:803–811. 2007. View Article : Google Scholar : PubMed/NCBI
5	Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, Lin EJ, Enriquez RF, McDonald MM, Zhang L, During MJ, et al: Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem. 282:19092–19102. 2007. View Article : Google Scholar : PubMed/NCBI
6	Yang K, Guan H, Arany E, Hill DJ and Cao X: Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J. 22:2452–2464. 2008. View Article : Google Scholar : PubMed/NCBI
7	Khor EC and Baldock P: The NPY system and its neural and neuroendocrine regulation of bone. Curr Osteoporos Rep. 10:160–168. 2012. View Article : Google Scholar : PubMed/NCBI
8	Horsnell H and Baldock PA: Osteoblastic actions of the neuropeptide Y system to regulate bone and energy homeostasis. Curr Osteoporos Rep. 14:26–31. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lin S, Boey D and Herzog H: NPY and Y receptors: Lessons from transgenic and knockout models. Neuropeptides. 38:189–200. 2004. View Article : Google Scholar : PubMed/NCBI
10	Allison SJ, Baldock PA and Herzog H: The control of bone remodeling by neuropeptide Y receptors. Peptides. 28:320–325. 2007. View Article : Google Scholar : PubMed/NCBI
11	Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM and Herzog H: Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 109:915–921. 2002. View Article : Google Scholar : PubMed/NCBI
12	Shi YC, Lin S, Wong IP, Baldock PA, Aljanova A, Enriquez RF, Castillo L, Mitchell NF, Ye JM, Zhang L, et al: NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One. 5:e113612010. View Article : Google Scholar : PubMed/NCBI
13	Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, Enriquez RF, Sainsbury A, Lamghari M, Simmons P, et al: Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem. 282:19082–19091. 2007. View Article : Google Scholar : PubMed/NCBI
14	Igwe JC, Jiang X, Paic F, Ma L, Adams DJ, Baldock PA, Pilbeam CC and Kalajzic I: Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem. 108:621–630. 2009. View Article : Google Scholar : PubMed/NCBI
15	Kurebayashi N, Sato M, Fujisawa T, Fukushima K and Tamura M: Regulation of neuropeptide Y Y1 receptor expression by bone morphogenetic protein 2 in C2C12 myoblasts. Biochem Biophys Res Commun. 439:506–510. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lee NJ, Nguyen AD, Enriquez RF, Doyle KL, Sainsbury A, Baldock PA and Herzog H: Osteoblast specific Y1 receptor deletion enhances bone mass. Bone. 48:461–467. 2011. View Article : Google Scholar : PubMed/NCBI
17	Bjurholm A, Kreicbergs A, Schultzberg M and Lerner UH: Parathyroid hormone and noradrenaline-induced enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line (UMR 106) is inhibited by neuropeptide Y. Acta Physiol Scand. 134:451–452. 1988. View Article : Google Scholar : PubMed/NCBI
18	Nakashima A, Katagiri T and Tamura M: Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem. 280:37660–37668. 2005. View Article : Google Scholar : PubMed/NCBI
19	Uyama M, Sato MM, Kawanami M and Tamura M: Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib. Genes Cells. 17:548–558. 2012. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Iizuka S, Oridate N, Nashimoto M, Fukuda S and Tamura M: Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing. PLoS One. 9:e1141212014. View Article : Google Scholar : PubMed/NCBI
22	Karsenty G: Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 9:183–196. 2008. View Article : Google Scholar : PubMed/NCBI
23	Teixeira L, Sousa DM, Nunes AF, Sousa MM, Herzog H and Lamghari M: NPY revealed as a critical modulator of osteoblast function in vitro: New insights into the role of Y1 and Y2 receptors. J Cell Biochem. 107:908–916. 2009. View Article : Google Scholar : PubMed/NCBI
24	Matic I, Matthews BG, Kizivat T, Igwe JC, Marijanovic I, Ruohonen ST, Savontaus E, Adams DJ and Kalajzic I: Bone-specific overexpression of NPY modulates osteogenesis. J Musculoskelet Neuronal Interact. 12:209–218. 2012.PubMed/NCBI
25	Ryoo HM, Lee MH and Kim YJ: Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene. 366:51–57. 2006. View Article : Google Scholar : PubMed/NCBI
26	Sousa DM, Baldock PA, Enriquez RF, Zhang L, Sainsbury A, Lamghari M and Herzog H: Neuropeptide Y Y1 receptor antagonism increases bone mass in mice. Bone. 51:8–16. 2012. View Article : Google Scholar : PubMed/NCBI